Haemoptysis, which is a challenging symptom accounting for 10-15% of all pulmonology consultations, may be associated with life-threatening medical conditions such as lung cancer [1-7]. Its aetiology and epidemiology vary widely among studies according to geographic locations and time of publication, epidemiological design, and diagnostic tests employed [2-8]. Bronchiectasis, malignancies, post-tuberculosis sequelae, and idiopathic bleedings have been recognised as the most frequent causes of haemoptysis in Europe over the last decade [3-7]. No guidelines exist suggesting an optimal work-up of symptoms, and data on the diagnostic yield of the most commonly prescribed examinations are limited [8]. The aim of this observational, prospective, multicentre study was to investigate the haemoptysis aetiology in association with its severity in an Italian population. We also evaluated the diagnostic yield of the prescribed diagnostic tests. The study was approved by the ethical committees of five Italian participating hospitals and registered at ClinicalTrials.gov (identifier: NCT02045394). Written informed consent was signed by the recruited patients, who were followed-up for 18 months. Herein, we report the findings of the baseline assessment. From July 2013 to September 2015, consecutive adult (i.e. ⩾18 years old) patients with haemoptysis were considered eligible. The following were considered as exclusion criteria: 1) aetiology of haemoptysis already detected (e.g. proven cancer-related and/or bronchiectasis-related haemoptysis); and 2) refusal to sign the informed consent. Patients were divided into three groups on the basis of the total amount of blood expectorated in 24 h [2, 3, 9]: mild (i.e. drops of blood to 20 mL in 24 h), moderate (i.e. 20-500 mL in 24 h), and severe (i.e. >500 mL in 24 h). All enrolled patients underwent physical examination and blood analysis. Subsequent tests deemed necessary for the diagnosis (i.e. sputum cultures, chest radiography, multi-detector chest computed tomography (CT), bronchoscopy, otorhinolaryngological evaluation, angiography) were chosen by the attending clinician on the basis of the clinical hypothesis and the symptom-driven diagnostic protocols of each hospital involved in the study. Final diagnosis was established in each centre, on the basis of the clinical and imaging evidence, by a multidisciplinary consensus that involved pulmonologists, radiologists, pathologists and otorhinolaryngologists. An electronic ad hoc form was created to collect demographic, epidemiological and clinical variables. Absolute and relative frequencies were used to summarise qualitative variables. Quantitative variables, for which the non-parametric distribution was assessed with the Shapiro-Wilk test, were summarised with medians and interquartile ranges (IQRs). 95% confidence intervals were computed to provide an interval estimation. The statistical software used for all the computations was Stata13.0 (StataCorp, College Station, TX, USA). During the study period, 606 patients (median age 67...
Two-stage revision with the use of an antibiotic-loaded cement spacer has spread widely as a successful treatment for THA infection. Between 1999 and 2008, 28 patients with infected THA were treated with two-stage implant revision using a preformed spacer. The spacer was left in situ for 5.5 months (range 1-13 months), and the patients were allowed to walk with partial weight bearing. At a mean follow-up of 53 months (range 18-106 months), recurrence of infection was observed in only one patient. Complications were observed in five patients: three spacer dislocations, one distal femoral fracture occurred during stem removal, and one femoral artery pseudo-aneurysm. The mean HHS increased from 43 points (range 13-77) to 82 points (range 35-96). Though small prospective studies are reported in literature, good eradication rate and good functional outcomes encourage for the use of an antibiotic-loaded cement spacer. The industrial production ensures procedure standardization, well-defined physical and chemical properties to the device and eliminates time necessary to intraoperatory manufacturing.
Glaucoma is a progressive, chronic optic neuropathy characterized by a typical visual field defects. Four main classes of topical medication are actually available on the market: beta-blockers, prostaglandins, alpha2-agonists, and topical carbonic anhydrase inhibitor to treat intraocular pressure (IOP). The aim of this review is to outline the efficacy of timolol and to evaluate the impact of this treatment on patients’ quality of life. Among beta-blockers, timolol is most used at three different concentrations: 0.1%, 0.25%, and 0.5%. While the first one is a gel, the other two products are solution. Timolol has few topical side effects, while it has some important systemic side effects on the cardiac and respiratory systems. The balance between efficacy and safety is always the main aspect to care patients. Because of the less efficacy of timolol 0.1% solution, the possibility to use carbomers as vehicle in the gel drops helped timolol 0.1 to be used in clinics, extending the time contact between the active ingredient and the surface of the cornea. Using preservative-free timolol 0.1 for treatment, IOP was at the same level of the other beta-blockers at higher concentration, but it was better tolerated. Preservative-free treatment improved the quality of life reducing dry-eye like symptoms; furthermore, the presence of an artificial tear in the medication bottle could help adherence. The once daily dosing improves compliance.
Précis: Gel stent implantation is a bleb-forming surgery designed to achieve predictable pressure drop. An early low intraocular pressure (IOP) is associated with the long-term success of the procedure. Purpose: To identify the variables associated with the success of the XEN procedure. Patients and Methods: This was part of a prospective, uncontrolled, consecutive case series study. Patients with primary open-angle glaucoma or pseudo-exfoliative glaucoma were included. All the patients underwent surgical XEN implant procedure with mitomycin-C subconjunctival injection 20 minutes before surgery. Success criteria were an off-medication IOP of 6 to 16 mm Hg 12 months after surgery; no additional glaucoma surgery; no visual threatening complications, no visual acuity loss >1 Snellen line. One eye per patient was considered for statistical analysis. A univariate Cox proportional hazard regression analysis was performed to identify potential risk factors for surgical failure. Then, a multivariate Cox model was built. Results: One hundred twenty-three patients were recruited in this study: 93 patients underwent XEN implantation alone whereas 30 the combined procedure with phacoemulsification and intraocular lens implantation. Univariate Cox regression showed that the day after surgery intraocular lens>9 mm Hg was associated with surgical failure (P=0.02) and a postoperative number of needlings ≥2 in the follow-up was also predictive of surgical failure (P<0.01). These data were confirmed by a multivariate model too. At 1 year the surgical success criteria were 76% in the group with 24-hour IOP≤9 mm Hg, whereas it was 43% when above 9 mm Hg (P=0.026). Conclusions: Our study shows that an early IOP≤9 mm Hg is predictive of the efficacy of the procedure during 1-year follow-up, whereas more than 2 needlings are predictive of failure.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.